Continuous Intravenous Pentoxifylline in Bone Marrow Transplant Recipients: First Results of a Pilot Study

  • D. W. Beelen
  • H. G. Sayer
  • M. Franke
  • M. E. Scheulen
  • K. Quabeck
  • M. Mohnke
  • M. Oidtmann
  • U. W. Schaefer
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

Recent preliminary clinical reports and a large array of experimental data suggest that pentoxifylline [(3,7-dimethyl-1-(5-oxohexyl)-xanthine, PTX] may be useful in ameliorating or preventing some of the indispensible toxicities and adverse events associated with the marrow transplant procedure [1,2]. To allow constant and high bioavailability of the compound and its major active metabolite 1-(5-hydroxyhexyl)-3,7-dimethylxanthine (5-OH-metabolite), a feasibility study in which PTX is given by continuous intravenous infusion is currently performed in patients with leukemia undergoing allogeneic bone marrow transplantation (BMT) at our institution. This study is aimed to define a tolerable dose-schedule of PTX and to investigate the pharmacology of the compound in this setting.

Keywords

Toxicity HPLC Leukemia Acetonitrile Cyclosporine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bianco JA, Appelbaum-FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78 (5): 1205–1211PubMedGoogle Scholar
  2. 2.
    Bianco JA, Almgren J, Kern DL, Ballard B, Roark K, Andrews F, Nemunaitis J, Shields T, Singer JW (1991) Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin Band cyclosporine. Transplantation 51 (4): 925–927PubMedCrossRefGoogle Scholar
  3. 3.
    Musch G, Hamoir T, Massart DL (1989) Determination of pentoxifylline and its 5-hydroxy metabolite in human plasma by solid-phase extraction and high performance liquid chromatography with ultraviolet detection. J Chromatogr 495: 215–226PubMedCrossRefGoogle Scholar
  4. 4.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–211PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • D. W. Beelen
    • 1
  • H. G. Sayer
    • 1
  • M. Franke
    • 1
  • M. E. Scheulen
    • 1
  • K. Quabeck
    • 1
  • M. Mohnke
    • 1
  • M. Oidtmann
    • 1
  • U. W. Schaefer
    • 1
  1. 1.University Hospital of EssenEssenGermany

Personalised recommendations